Andrew Baum
Stock Analyst at Citigroup
(2.81)
# 1,746
Out of 4,837 analysts
63
Total ratings
69.77%
Success rate
11.98%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Downgrades: Neutral | $115 → $84 | $77.97 | +7.73% | 14 | May 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $23.52 | +23.30% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $47.87 | +35.78% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $33.09 | +20.88% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $184.85 | +16.31% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $747.01 | +19.81% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $9.79 | +2.20% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $38.40 | - | 2 | Jul 5, 2017 |
Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115 → $84
Current: $77.97
Upside: +7.73%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $23.52
Upside: +23.30%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $47.87
Upside: +35.78%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $33.09
Upside: +20.88%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $184.85
Upside: +16.31%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $747.01
Upside: +19.81%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $9.79
Upside: +2.20%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $38.40
Upside: -